Tuberculosis and Respiratory Diseases10.4046/trd.2022.0055202386133-46An Open-Label, Multicentre, Observational, Post-Marketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean PatientsEun-Yeong Cho, Jung-Eun Cho, Eun-Bin Lee, Seung Soo Yoo, Jung Hyun Chang,,
Clinical Therapeutics10.1016/j.clinthera.2014.05.00220143671016-1027.e2Effects of Moderate Hepatic Impairment on the Pharmacokinetic Properties and Tolerability of Umeclidinium and Vilanterol in Inhalational Umeclidinium Monotherapy and Umeclidinium/Vilanterol Combination Therapy: An Open-Label, Nonrandomized StudyRashmi Mehta, Kelly Hardes, Dennis Kelleher, Andrew Preece, Lee Tombs, Noushin Brealey,
International Journal of Chronic Obstructive Pulmonary Disease10.2147/copd.s408592013159Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label studyRashmi Mehta, Kelleher, Andrew Preece, Hughes, Crater
The Lancet Respiratory Medicine10.1016/s2213-2600(14)70065-7201426472-486Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsMarc Decramer, Antonio Anzueto, Edward Kerwin, Thomas Kaelin, Nathalie Richard, Glenn Crater, Maggie Tabberer, Stephanie Harris, Alison Church,
Infection & Chemotherapy10.3947/ic.2020.01242021533539Safety and Effectiveness of Darunavir in Korean Patients with Human Immunodeficiency Virus 1 Infection: A Post-Marketing Observational StudyHyeongyeong Kim, Youngdoe Kim, Jiho Kang,,
Journal of Asthma and Allergy10.2147/jaa.s3059182021Volume 14809-819Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label StudySoichiro Hozawa, Hiroyuki Ohbayashi, Michiko Tsuchiya, Yu Hara, Laurie A Lee, Takashi Nakayama, Jun Tamaoki, Andrew Fowler, Takanobu Nishi,
Clinical Drug Investigation10.1007/s40261-020-00941-32020409847-859Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational StudyTomohiko Ishikawa, Tatsushi Maeda, Teruo Hashimoto, Tetsuya Nakagawa, Kazuhito Ichikawa, Yasushi Sato, Yoshihiko Kanno,,
Indian Heart Journal10.1016/j.ihj.2014.05.0022014663340-344WIN OVER study: Efficacy and safety of olmesartan in Indian hypertensive patients: Results of an open label, non-comparative, multi-centric, post marketing observational studyD.K. Kumbla, S. Kumar, Y.V. Reddy, A. Trailokya, M. Naik,
Advances in Therapy10.1007/s12325-020-01293-220203752442-2459Long-Term Safety and Efficacy of Sitagliptin for Type 2 Diabetes Mellitus in Japan: Results of a Multicentre, Open-Label, Observational Post-Marketing Surveillance StudyKen Yoshikawa, Akira Tsuchiya, Tomoyuki Kido, Tomohiro Ota, Keiko Ikeda, Mika Iwakura, Yoshikazu Maeda, Shinichiroh Maekawa,,
Annals of Dermatology10.5021/ad.2018.30.4.4412018304441An Open Label, Multi-Center, Non-Interventional Post-Marketing Surveillance to Monitor the Safety and Efficacy of ALTARGO® (Retapamulin) Administered in Korean Patients According to the Prescribing InformationWoosung Hong, Yil-Seob Lee, Chun-Wook Park, Moon-Soo Yoon, Young Suck Ro,,